Skip to main content
. 2012 Feb;19(1):L1–L4. doi: 10.1530/ERC-11-0287

Figure 1.

Figure 1

Downstaging of gastroenteropancreatic tumours (arrows) after TeBeSa combination therapy. MRI details shown before treatment (a) and (c) and after six cycles (b) and (d) for two patients with a pancreatic (a)/(b) and a duodenal tumour (c)/(d).